Quick Answer
BIOCRYST PHARMACEUTICALS INC reported Operating Income Loss of $340.99 million for the year ending 2025.
- BIOCRYST PHARMACEUTICALS INC showed an increase of +13,508.9% in Operating Income Loss from 2024 to 2025.
- This data is from BIOCRYST PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: -$10.33 million | Q3 2010: -$10.99 million | Q1 2011: -$11.50 million | Q2 2011: -$14.24 million | Q3 2011: -$12.81 million | Q1 2012: -$5.00 million | Q2 2012: -$10.18 million | Q3 2012: -$8.02 million | Q1 2013: -$5.32 million | Q2 2013: -$12.14 million | Q3 2013: -$6.93 million | Q1 2014: -$7.39 million | Q2 2014: -$11.62 million | Q3 2014: -$11.61 million | Q1 2015: -$14.43 million | Q2 2015: $5.34 million | Q3 2015: -$13.16 million | Q1 2016: -$19.05 million | Q2 2016: -$12.13 million | Q3 2016: -$9.24 million | Q1 2017: -$10.69 million | Q2 2017: -$15.52 million | Q3 2017: -$13.35 million | Q1 2018: -$22.21 million | Q2 2018: -$18.25 million | Q3 2018: -$28.49 million | Q1 2019: -$29.33 million | Q2 2019: -$34.92 million | Q3 2019: -$35.10 million | Q1 2020: -$40.98 million | Q2 2020: -$38.51 million | Q3 2020: -$42.86 million | Q1 2021: -$51.38 million | Q2 2021: -$29.58 million | Q3 2021: -$44.58 million | Q1 2022: -$49.96 million | Q2 2022: -$34.72 million | Q3 2022: -$17.45 million | Q1 2023: -$28.42 million | Q2 2023: -$20.70 million | Q3 2023: -$11.92 million | Q1 2024: -$14.49 million | Q2 2024: $8.76 million | Q3 2024: $7.69 million | Q1 2025: $21.23 million | Q2 2025: $29.79 million | Q3 2025: $29.59 million.
- Over the full 17 years of available data (2009 to 2025), BIOCRYST PHARMACEUTICALS INC's Operating Income Loss has grown by 2,582.3%.
- Historical annual values: Fiscal year 2025: $340.99 million | Fiscal year 2024: -$2.54 million | Fiscal year 2023: -$103.71 million | Fiscal year 2022: -$148.44 million | Fiscal year 2021: -$177.72 million | Fiscal year 2020: -$174.76 million | Fiscal year 2019: -$99.46 million | Fiscal year 2018: -$94.22 million | Fiscal year 2017: -$57.41 million | Fiscal year 2016: -$48.61 million | Fiscal year 2015: -$39.44 million | Fiscal year 2014: -$45.77 million | Fiscal year 2013: -$30.72 million | Fiscal year 2012: -$33.89 million | Fiscal year 2011: -$49.59 million | Fiscal year 2010: -$34.36 million | Fiscal year 2009: -$13.74 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: